Recent Updates
Recently added Catalysts

HFA-152a, HFA-134a, Radiolabeled saline

Phase 1

Asthma | Unknown | Respiratory |GSK plc|Last Updated: Apr 14, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06506266Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy ParticipantsPHASE1 COMPLETED 24Jul 29, 2024Oct 24, 2024Apr 14, 20261 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Percent Radiolabeled Particle Retention-time Curve up to 4 Hours [AUC(0-4h)] After Nebulized 99mTechnetium (99mTc) Inhalation on Day 7
At 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, and 240 minutes on Day 7

\[AUC(0-4h)\] was assessed for Mucociliary clearance (MCC) in participants following administration of nebulized 99mTc on Day 7. Gamma scintigraphy was utilized to conduct assessments.

Secondary Endpoints
Percentage of Radiolabeled Particle Retention at 1 Hour After Nebulized 99mTechnetium (99mTc) Inhalation on Day 7
1 hour after inhalation on Day 7
Percentage of Radiolabeled Particle Retention at 1.5 Hours After Nebulized 99mTechnetium (99mTc) Inhalation on Day 7
1.5 hours after inhalation on Day 7
Percentage of Radiolabeled Particle Retention at 3 Hours After Nebulized 99mTechnetium (99mTc) Inhalation on Day 7
3 hours after inhalation on Day 7
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
HFA-152a followed by HFA-134aEXPERIMENTAL -
HFA-134a followed by HFA-152aEXPERIMENTAL -
Interventions
NameTypeDescription
HFA-152aOTHERHFA-152a is administered via oral inhalation
HFA-134aOTHERHFA-134a is administered via oral inhalation
Radiolabeled saline solutionOTHERRadiolabeled saline solution is administered via oral inhalation
Unlock Study Design Details
Eligibility Criteria
Age Range30 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: Participants are eligible to be included in the study only if all following criteria apply: * Male or Female, age 30 to 55 years * Body Mass Index (BMI): 18.0 to 32.0 kg/m2, inclusive, at screening * Weight: ≥50 kg * Nonsmokers or ex-smokers for more than 6 months with a smokin...

Countries:United Kingdom
Unlock Eligibility Criteria